ArticleDrug delivery and translational research2020
Characterization of a liposomal copper(II)-quercetin formulation suitable for parenteral use.
Article in Drug delivery and translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 39 citations in OpenAlex.
- Development of new liposomal formulations of quercetin - in vitro study.Scientific reports · 2026Article
- Nanotechnology-Enhanced Delivery and Bioactivity of Dietary Flavonoids: Overcoming Bioavailability Barriers for Targeted Antimicrobial and Antiviral Therapies-A Comprehensive Review.International journal of nanomedicine · 2026Review
- Targeting Senescence, Oxidative Stress, and Inflammation: Quercetin-Based Strategies for Ocular Diseases in Older Adults.Clinical interventions in aging · 2025Review
- Quercetin promotes production of secondary hair follicle stem cells in cashmere goat: a mechanistic study.Frontiers in veterinary science · 2025Article
- Liposomal Formulations of Metallodrugs for Cancer Therapy.International journal of molecular sciences · 2024Review
- Accumulation of liposomes in metastatic tumor sites is not necessary for anti-cancer drug efficacy.Journal of translational medicine · 2024Article
- Quercetin, a Flavonoid with Great Pharmacological Capacity.Molecules (Basel, Switzerland) · 2024Review
- COVID-19 associated thyroid dysfunction and other comorbidities and its management using phytochemical-based therapeutics: a natural way.Bioscience reports · 2023Review
- Plant-derived chelators and ionophores as potential therapeutics for metabolic diseases.Chemical Society reviews · 2023Review
- Recent Advances in Nanoformulations for Quercetin Delivery.Pharmaceutics · 2023Review
- Potential Pharmaceutical Applications of Quercetin in Cardiovascular Diseases.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Suppression of Intracellular Reactive Oxygen Species in Human Corneal Epithelial Cells via the Combination of Quercetin Nanoparticles and Epigallocatechin Gallate and In Situ Thermosensitive Gel Formulation for Ocular Drug Delivery.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Fighting the Antibiotic Crisis: Flavonoids as Promising Antibacterial Drugs AgainstFrontiers in cellular and infection microbiology · 2021Review
- Improvement in the Pharmacological Profile of Copper Biological Active Complexes by Their Incorporation into Organic or Inorganic Matrix.Molecules (Basel, Switzerland) · 2020Review
- Copper Coordination Compounds as Biologically Active Agents.International journal of molecular sciences · 2020Review
- Preparation of an oil suspension containing ondansetron hydrochloride as a sustained release parenteral formulation.Drug delivery and translational research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
Quercetin (3,3',4',5,7-pentahydroxyflavone) is a naturally derived flavonoid that is commonly found in fruits and vegetables. There is mounting evidence to suggest that quercetin has potential anticancer effects and appears to interact synergistically when used in combination with approved chemotherapeutic agents such as irinotecan and cisplatin. Unfortunately, quercetin has shown limited clinical utility, partly due to low bioavailability related to its poor aqueous solutions (< 10 μg/mL). In this study, liposomal formulations of quercetin were developed by exploiting quercetin's ability to bind copper. Quercetin powder was added directly to pre-formed copper-containing liposomes (2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and cholesterol (CHOL) (55:45 M ratio)). As a function of time and temperature, the formation of copper-quercetin was measured. Using this methodology, a final quercetin-to-lipid (mol:mol) ratio of 0.2 was achievable and solutions containing quercetin at concentrations of > 5 mg/mL were attained, representing at least a > 100-fold increase in apparent solubility. The resulting formulation was suitable for intravenous dosing with no overt toxicities when administered at doses of 50 mg/kg in mice. Pharmacokinetic studies demonstrated that the copper-quercetin formulations had an AUC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.